MetaCap

Minerva Neurosciences (NERV) vs Unicycive Therapeutics (UNCY)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Unicycive Therapeutics (UNCY) has outperformed Minerva Neurosciences (NERV) over the past year, losing 38.0% versus a loss of 49.2%. Over five years, NERV leads with a -76.4% price change compared with -88.5% for UNCY. Minerva Neurosciences is the larger company by market cap ($99.7 million vs $97.8 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

NERV-49.24%UNCY-37.96%
+113%+28%-57%
Nov 21, 20251 yearNov 20, 2026
NERV-77.68%UNCY-87.07%
+57%-19%-95%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

NERV versus UNCY key metrics
MetricNERVUNCY
Share price$2.00$3.35
Market cap$99.67M$97.77M
1-day change-5.66%-5.10%
YTD return-50.25%-41.94%
1-year return-49.24%-37.96%
5-year return-76.42%-88.53%
Forward P/E—4.86
EPS (TTM)$-33.83$-1.64
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-293.42M$-26.55M
52-week high$8.80$8.74
52-week low$1.96$3.33
Distance from 52-week high-77.27%-61.67%
Analyst consensusbuystrong_buy
Avg. price target upside+416.50%+685.07%
Average volume164.71K963.80K
Shares outstanding49.84M29.18M
Employees721
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • UNCY has outperformed NERV by 11.3 percentage points over the past year.

About Minerva Neurosciences

NERV stock →

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia.

Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees

About Unicycive Therapeutics

UNCY stock →

Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator, which is in Phase I clinical trial for the treatment of acute kidney injury and pre-clinical stage for the treatment of chronic kidney disease.

Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees

NERV vs UNCY FAQ

Which is bigger, Minerva Neurosciences or Unicycive Therapeutics?

Minerva Neurosciences (NERV) is larger, with a market capitalization of $99.67M compared with $97.77M for Unicycive Therapeutics (UNCY).

Which stock has performed better over the past year, NERV or UNCY?

UNCY returned -37.96% over the past 12 months, compared with -49.24% for NERV (price return, excluding dividends). Past performance does not predict future results.

Are Minerva Neurosciences and Unicycive Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons